In just a few weeks, STAT will again partner with HUBweek, Boston’s future-thinking festival where art, science, and technology collide, for events that underscore our mission to cover the frontiers of health and science.
Last year, we discussed the future of cancer treatment, how to take innovation to the masses, and the challenges and opportunities for women in science fields. We dove into exclusive lab spaces through 360-degree videos and took an intimate look at a group of friends who came of age as the opioid epidemic morphed into a national nightmare.
Here’s our lineup for this year. And it is even more convenient because our events will all be on Tuesday, Oct. 9 at Broad Institute of MIT and Harvard in Cambridge. We’ll treat you to coffee, snacks, and, I’m certain, engaging conversation around the following topics:
CRISPR: from lab to clinic
8:15 a.m.-9:30 a.m.
Advances in use of the CRISPR genome editing technology have been arriving at breakneck speed. But even as the first clinical trials of the technique are expected to start before the end of the year, scientists have found that CRISPR might in some circumstances pose unexpected risks to patients. Join us for a panel discussion — led by Senior Science Writer Sharon Begley — that explores the newest forms and uses of CRISPR, its potential to cure now-incurable diseases, and the challenges of turning a revolutionary lab technique into a therapy. Register here.
The path forward for women in science
10 a.m.-11:15 a.m.
In the past year, the worlds of medicine and science have been part of a broad reckoning about the obstacles that can block women from advancing and feeling comfortable in the workplace. Universities, hospitals, and life sciences companies are launching and expanding gender diversity initiatives, but what’s really moving the needle? San Francisco Correspondent Rebecca Robbins will lead a discussion about what’s changing — and what’s not — in laboratories, executive suites, and boardrooms. Register here.
How are AI and Big Data disrupting drug discovery?
12 p.m.-1 p.m.
Drug development is a costly and uncertain process. Companies spend billions of dollars developing new drugs only to find out they don’t work so well in the real world. But the increasing utility of artificial intelligence is promising to make this work cheaper, faster, and more effective. STAT’s disruption reporter, Casey Ross, will lead a thought provoking conversation with key industry experts about how drug developers, doctors, and bioinformatics researchers are using artificial intelligence to revolutionize the search for breakthrough therapies. Register here.
It’ll be a spectacular day of meaningful connections and thought-provoking discussion. All three events are free. We hope you will join us.
About the Author Reprints
